ABCG2 p.Arg482Met

Predicted by SNAP2: A: D (91%), C: D (85%), D: D (95%), E: D (95%), F: D (91%), G: D (95%), H: D (95%), I: D (85%), K: D (85%), L: D (91%), M: D (85%), N: D (95%), P: D (95%), Q: D (95%), S: D (91%), T: D (91%), V: D (91%), W: D (95%), Y: D (95%),
Predicted by PROVEAN: A: D, C: D, D: D, E: D, F: D, G: D, H: D, I: D, K: D, L: D, M: D, N: D, P: D, Q: D, S: D, T: D, V: D, W: D, Y: D,

[switch to compact view]
Comments [show]
Publications
[hide] Allen JD, Jackson SC, Schinkel AH
A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance.
Cancer Res. 2002 Apr 15;62(8):2294-9., 2002-04-15 [PMID:11956086] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E
Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.
Cancer Res. 2002 Sep 1;62(17):5035-40., 2002-09-01 [PMID:12208758] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Ozvegy C, Varadi A, Sarkadi B
Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.
J Biol Chem. 2002 Dec 13;277(50):47980-90. Epub 2002 Oct 8., 2002-12-13 [PMID:12374800] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, Baba M
Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.
Mol Pharmacol. 2003 Jan;63(1):65-72., [PMID:12488537] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Miwa M, Tsukahara S, Ishikawa E, Asada S, Imai Y, Sugimoto Y
Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
Int J Cancer. 2003 Dec 10;107(5):757-63., 2003-12-10 [PMID:14566825] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS, Bates SE
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity.
Br J Cancer. 2003 Nov 17;89(10):1971-8., 2003-11-17 [PMID:14612912] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Han B, Zhang JT
Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
Curr Med Chem Anticancer Agents. 2004 Jan;4(1):31-42., [PMID:14754410] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Sarkadi B, Ozvegy-Laczka C, Nemet K, Varadi A
ABCG2 -- a transporter for all seasons.
FEBS Lett. 2004 Jun 1;567(1):116-20., 2004-06-01 [PMID:15165903] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Wang X, Nitanda T, Shi M, Okamoto M, Furukawa T, Sugimoto Y, Akiyama S, Baba M
Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein.
Biochem Pharmacol. 2004 Oct 1;68(7):1363-70., 2004-10-01 [PMID:15345326] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Ozvegy-Laczka C, Koblos G, Sarkadi B, Varadi A
Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.
Biochim Biophys Acta. 2005 Feb 1;1668(1):53-63., 2005-02-01 [PMID:15670731] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, Sarkadi B, Bates SE
Single nucleotide polymorphisms modify the transporter activity of ABCG2.
Cancer Chemother Pharmacol. 2005 Aug;56(2):161-72. Epub 2005 Apr 19., [PMID:15838659] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Krishnamurthy P, Schuetz JD
The ABC transporter Abcg2/Bcrp: role in hypoxia mediated survival.
Biometals. 2005 Aug;18(4):349-58., [PMID:16158227] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Shafran A, Ifergan I, Bram E, Jansen G, Kathmann I, Peters GJ, Robey RW, Bates SE, Assaraf YG
ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates.
Cancer Res. 2005 Sep 15;65(18):8414-22., 2005-09-15 [PMID:16166320] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Cervenak J, Andrikovics H, Ozvegy-Laczka C, Tordai A, Nemet K, Varadi A, Sarkadi B
The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology.
Cancer Lett. 2006 Mar 8;234(1):62-72. Epub 2005 Dec 7., 2006-03-08 [PMID:16337740] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Ejendal KF, Diop NK, Schweiger LC, Hrycyna CA
The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding.
Protein Sci. 2006 Jul;15(7):1597-607., [PMID:16815914] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Sarkadi B, Homolya L, Szakacs G, Varadi A
Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system.
Physiol Rev. 2006 Oct;86(4):1179-236., [PMID:17015488] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Telbisz A, Hegedus C, Ozvegy-Laczka C, Goda K, Varady G, Takats Z, Szabo E, Sorrentino BP, Varadi A, Sarkadi B
Antibody binding shift assay for rapid screening of drug interactions with the human ABCG2 multidrug transporter.
Eur J Pharm Sci. 2012 Jan 23;45(1-2):101-9. Epub 2011 Nov 17., [PMID:22115866] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]